Related Experiment Video

Updated: May 1, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K

Genetic variation and coronary atherosclerosis in patients with systemic lupus erythematosus

C P Chung1, J F Solus2, A Oeser2

  • 1Departments of Medicine, Vanderbilt University, Nashville, TN, USA c.chung@vanderbilt.edu.

Lupus
|April 5, 2014
PubMed

Insights

Genetic variations may influence coronary artery disease in systemic lupus erythematosus (SLE) patients. Researchers identified potential gene links to coronary atherosclerosis, but further studies are needed for confirmation.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Rheumatology

Background:

  • Systemic lupus erythematosus (SLE) significantly increases mortality due to coronary artery disease (CAD).
  • Traditional cardiovascular risk factors do not fully explain the elevated risk in SLE patients.
  • The role of genetic predisposition in CAD development within SLE is under investigation.

Purpose of the Study:

  • To investigate the hypothesis that genetic variations contribute to coronary atherosclerosis in patients with SLE.
  • To identify specific single-nucleotide polymorphisms (SNPs) associated with coronary artery calcium (CAC) in SLE.

Main Methods:

  • Genotyping of 152 candidate genes related to autoimmune or cardiovascular risk in 125 SLE patients.
  • Detection of coronary artery calcium (CAC) using electron-beam computed tomography.
  • Statistical analysis of SNP genotypes and CAC presence, adjusting for age, sex, and race.

Main Results:

  • Coronary artery calcium (CAC) was detected in 26% of the SLE patients studied.
  • Polymorphisms in 20 candidate genes showed nominal association with CAC presence (p-values 0.001-0.047).
  • No associations remained significant after false discovery rate adjustment, indicating a need for replication.

Conclusions:

  • Genetic variations in genes like ADAM33, ADIPOQ, and IRF5 may be nominally associated with coronary atherosclerosis in SLE.
  • Some identified genes are known SLE susceptibility genes or have been linked to cardiovascular disease in other populations.
  • Replication studies in larger SLE cohorts are essential to validate these findings and clarify the genetic contribution to CAD in SLE.

Keywords:
SNPSystemic lupus erythematosusatherosclerosisgenetic variation

More Related Videos

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.0K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.0K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138